Childhood medulloblastoma;Le médulloblastome de l'enfant

Archives de Pediatrie

Volumn 15, Issue 12, 2008, Pages 1794-1804

  Yazigi Rivard, L ^a   Masserot, C ^a   Lachenaud, J ^a   Diebold Pressac, I ^a   Aprahamian, A ^a   Avran, D ^a   Doz, F ^a  

^a INSTITUT CURIE   (France)

Author keywords

[No Author keywords available]

Indexed keywords

LOMUSTINE; VINCRISTINE;

BASAL CELL NEVUS SYNDROME; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER RISK; CANCER SURGERY; CEREBROSPINAL FLUID ANALYSIS; COGNITION; DISEASE PREDISPOSITION; FOLLOW UP; HEADACHE; HIGH RISK PATIENT; HUMAN; MEDULLOBLASTOMA; NEUROECTODERM TUMOR; NUCLEAR MAGNETIC RESONANCE IMAGING; RADIATION DOSE; SHORT SURVEY; SURVIVAL; VOMITING;

AGE FACTORS; CEREBELLAR NEOPLASMS; CHILD; CHILD, PRESCHOOL; COMBINED MODALITY THERAPY; FEMALE; FOLLOW-UP STUDIES; HUMANS; MAGNETIC RESONANCE IMAGING; MALE; MEDULLOBLASTOMA; META-ANALYSIS AS TOPIC; NEOPLASM METASTASIS; NEOPLASMS, SECOND PRIMARY; PROGNOSIS; PROSPECTIVE STUDIES; RADIOTHERAPY; RADIOTHERAPY DOSAGE; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RISK FACTORS; TREATMENT OUTCOME;

EID: 56949091075     PISSN: 0929693X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.arcped.2008.09.021     Document Type: Short Survey

References (52)

1. Steliarova-Foucher E., Stiller C., Lacour B., et al. International Classification of Childhood Cancer, third edition. Cancer 103 (2005) 1457-1467
2. Sarkar C., Pramanik P., Karak A.K., et al. Are childhood and adult medulloblastomas different? A comparative study of clinicopathological features, proliferation index and apoptotic index. J Neurooncol 59 (2002) 49-61
3. Gold E., Gordis L., Tonascia J., et al. Increased risk of brain tumors in children exposed to barbiturates. J Natl Cancer Inst 61 (1978) 1031-1034
4. Gorlin R.J. Nevoid basal cell carcinoma (Gorlin) syndrome. Genet Med 6 (2004) 530-539
5. Amlashi S., Riffaud L., Brassier G., et al. Nevoid basal cell carcinoma syndrome: relation with desmoplastic medulloblastoma in infancy. A population-based study and review of the literature. Cancer 98 (2003) 618-624
6. Taylor M.D., Liu L., Raffel C., et al. Mutations in SUFU predispose to medulloblastoma. Nat Genet 31 (2002) 306-310
7. Galiatsatos P., and Foulkes W.D. Familial adenomatous polyposis. Am J Gastroenterol 101 (2006) 385-398
8. Hsiung S.H. Rubinstein-Taybi syndrome (broad thumb-hallux syndrome). Dermatol Online J 10 (2004) 2
9. Adesina A.M., Nalbotanglu J., and Cavenee W.K. p53 gene mutation and mdm2 gene amplification are uncommon in medulloblastoma. Cancer Res 54 (1994) 5649-5651
10. Giangaspero F., Perilongo G., Fondelli M.P., et al. Medulloblastoma with extensive nodularity: a variant with favorable prognosis. J Neurosurg 91 (1999) 971-977
11. Lamont J.M., McManamy C.S., Pearson A.D., et al. Combined histopathological and molecular cytogenetic stratification of medulloblastoma patients. Clin Cancer Res 10 (2004) 5482-5493
12. Janss A.J., Yachnis A.T., Silber J.H., et al. Glial differentiation predicts poor clinical outcome in primitive neuroectodermal brain tumors. Ann Neurol 39 (1996) 481-489
13. Ellison D.W., Onilude O.E., Lindsey J.C., et al. Beta-catenin status predicts a favorable outcome in childhood medulloblastoma: the United Kingdom Children's Cancer Study Group Brain Tumour Committee. J Clin Oncol 23 (2005) 7951-7957
14. Gilbertson R.J., Pearson A.D., Perry R.H., et al. Prognostic significance of the c-erbB-2 oncogene product in childhood medulloblastoma. Br J Cancer 71 (1995) 473-477
15. Fangusaro J.R., Jiang Y., Holloway M.P., et al. Survivin, Survivin-2B, and Survivin-deItaEx3 expression in medulloblastoma: biologic markers of tumour morphology and clinical outcome. Br J Cancer 92 (2005) 359-365
16. Min H.S., Lee Y.J., Park K., et al. Medulloblastoma: histopathologic and molecular markers of anaplasia and biologic behavior. Acta Neuropathol 112 (2006) 13-20
17. Rossi M.R., Conroy J., McQuaid D., et al. Array CGH analysis of pediatric medulloblastomas. Genes Chromosomes Cancer 45 (2006) 290-303
18. Gilbertson R.J. Medulloblastoma: signalling a change in treatment. Lancet Oncol 5 (2004) 209-218
19. Pietsch T., Taylor M.D., and Rutka J.T. Molecular pathogenesis of childhood brain tumors. J Neurooncol 70 (2004) 203-215
20. Chang C.H., Housepian E.M., and Herbert Jr. C. An operative staging system and a megavoltage radiotherapeutic technic for cerebellar medulloblastomas. Radiology 93 (1969) 1351-1359
21. Packer R.J., Rood B.R., and MacDonald T.J. Medulloblastoma: present concepts of stratification into risk groups. Pediatr Neurosurg 39 (2003) 60-67
22. Zelter P.M., Boyett J.M., and Finlay J.L. Metastasis stage, adjuvant treatement, and residual tumor are prognostic factors for medulloblastoma in children: conclusions from the Children's Cancer Group 921 randomized phase III study. J Clin Oncol 17 (1999) 832-845
23. Deutsch M., Thomas P.R., Krischer J., et al. Results of a prospective randomized trial comparing standard dose neuraxis irradiation (3600 cGy/20) with reduced neuraxis irradiation (2340 cGy/13) in patients with low-stage medulloblastoma. A Combined Children's Cancer Group-Pediatric Oncology Group Study. Pediatr Neurosurg 24 (1996) 167-176
24. Thomas P.R., Deutsch M., Kepner J.L., et al. Low-stage medulloblastoma: final analysis of trial comparing standard-dose with reduced-dose neuraxis irradiation. J Clin Oncol 18 (2000) 3004-3011
25. Bailey C.C., Gnekow A., Wellek S., et al. Prospective randomised trial of chemotherapy given before radiotherapy in childhood medulloblastoma. International Society of Paediatric Oncology (SIOP) and the (German) Society of Paediatric Oncology (GPO): SIOP II. Med Pediatr Oncol 25 (1995) 166-178
26. Packer R.J., Goldwein J., Nicholson H.S., et al. Treatment of children with medulloblastoma with reduced-dose craniospinal radiation therapy and adjuvant chemotherapy: a Children's Cancer Group Study. J Clin Oncol 17 (1999) 2127-2136
27. Oyharcabal-Bourden V., Kalifa C., Gentet J.C., et al. Standard-risk medulloblastoma treated by adjuvant chemotherapy followed by reduced-dose craniospinal radiation therapy: a French Society of Pediatric Oncology Study. J Clin Oncol 23 (2005) 4726-4734
28. Carrie C., Muracciole X., Gomez F., et al. French Society of Pediatric Oncology. Conformal radiotherapy, reduced boost volume, hyperfractionated radiotherapy, and online quality control in standard-risk medulloblastoma without chemotherapy: results of the French M-SFOP 98 protocol. Int J Radiat Oncol Biol Phys 63 (2005) 711-716
29. Taylor R.E., Bailey C.C., Robinson K., et al. Results of a randomized study of preradiation chemotherapy versus radiotherapy alone for nonmetastatic medulloblastoma: The International Society of Paediatric Oncology/United Kingdom Children's Cancer Study Group PNET-3 Study. J Clin Oncol 21 (2003) 1581-1591
30. Evans A.E., Jenkin R.D., Sposto R., et al. The treatment of medulloblastoma. Results of a prospective randomized trial of radiation therapy with and without CCNU, vincristine, and prednisone. J Neurosurg 72 (1990) 572-582
31. Gajjar A., Chintagumpala M., Ashley D., et al. Risk-adapted craniospinal radiotherapy followed by high-dose chemotherapy and stem-cell rescue in children with newly diagnosed medulloblastoma (St Jude Medulloblastoma-96): long-term results from a prospective, multicentre trial. Lancet Oncol 7 (2006) 813-820
32. Duffner P.K., Horowitz M.E., Krischer J.P., et al. Postoperative chemotherapy and delayed radiation in children less than 3 years of age with malignant brain tumors. N Engl J Med 328 (1993) 1725-1731
33. Geyer J.R., Sposto R., Jennings M., et al. Multiagent chemotherapy and deferred radiotherapy in infants with malignant brain tumors: a report from the Children's Cancer Group. J Clin Oncol 23 (2005) 7621-7631
34. Grill J., Sainte-Rose C., Jouvet A., et al. Treatment of medulloblastoma with postoperative chemotherapy alone: an SFOP prospective trial in young children. Lancet Oncol 6 (2005) 573-580
35. Rutkowski S., Bode U., Deinlein F., et al. Treatment of early childhood medulloblastoma by postoperative chemotherapy alone. N Engl J Med 352 (2005) 978-986
36. Ribi K., Relly C., Landolt M.A., et al. Outcome of medulloblastoma in children: long-term complications and quality of life. Neuropediatrics 36 (2005) 357-365
37. Barr R.D., Simpson T., Whitton A., et al. Health-related quality of life in survivors of tumours of the central nervous system in childhood: a preference-based approach to measurement in a cross-sectional study. Eur J Cancer 35 (1999) 248-255
38. Grill J., Kieffer V., and Kalifa C. Measuring the neurocognitive side-effects of irradiation in children with brain tumors. Pediatr Blood Cancer 42 (2004) 452-456
39. Mulhern R.K. Correlation of the Health Utilities Index Mark 2 cognition scale and neuropsychological functioning among survivors of childhood medulloblastoma. Int J Cancer suppl 12 (1999) 91-94
40. Mulhern R.K., Merchant T.E., Gajjar A., et al. Late neurocognitive sequelae in survivors of brain tumours in childhood. Lancet Oncol 5 (2004) 399-408
41. Fouladi M., Gilger E., Kocak M., et al. Intellectual and functional outcome of children 3 years old or younger who have CNS malignancies. J Clin Oncol 23 (2005) 7152-7160
42. Ross L., Johansen C., Dalton S.O., et al. Psychiatric hospitalizations among survivors of cancer in childhood or adolescence. N Engl J Med 349 (2003) 650-657
43. Grill J., Viguier D., Kieffer V., et al. Critical risk factors for intellectual impairment in children with posterior fossa tumors: the role of cerebellar damage. J Neurosurg 101 (2004) 152-158
44. Kieffer-Renaux V., Viguier D., Raquin M.A., et al. Therapeutic schedules influence the pattern of intellectual decline after irradiation of posterior fossa tumors. Pediatr Blood Cancer 45 (2005) 814-819
45. Packer R.J., Gurney J.G., Punyko J.A., et al. Long-term neurologic and neurosensory sequelae in adult survivors of a childhood brain tumor: childhood cancer survivor study. J Clin Oncol 21 (2003) 3255-3261
46. Gleeson H.K., and Shalet S.M. The impact of cancer therapy on the endocrine system in survivors of childhood brain tumors. Endocr Relat Cancer 11 (2004) 589-602
47. Gurney J.G., Kadan-Lottick N.S., Packer R.J., et al. Endocrine and cardiovascular late effects among adult survivors of childhood brain tumors: Childhood Cancer Survivor Study. Cancer 97 (2003) 663-673
48. Packer R.J., Boyett J.M., Janss A.J., et al. Growth hormone replacement therapy in children with medulloblastoma: use and effect on tumor control. J Clin Oncol 19 (2001) 480-487
49. Gaspar L.E., Dawson D.J., Tilley-Gulliford S.A., et al. Medulloblastoma: long-term follow-up of patients treated with electron irradiation of the spinal field. Radiology 180 (1991) 867-870
50. Odame I., Duckworth J., Talsma D., et al. Osteopenia, physical activity and health-related quality of life in survivors of brain tumors treated in childhood. Pediatr Blood Cancer 46 (2006) 357-362
51. Goldstein A.M., Yuen J., and Tucker M.A. Second cancers after medulloblastoma: population-based results from the United States and Sweden. Cancer Causes Control 8 (1997) 865-871
52. Duffner P.K., Krischer J.P., Horowitz M.E., et al. Second malignancies in young children with primary brain tumors following treatment with prolonged postoperative chemotherapy and delayed irradiation: a Pediatric Oncology Group study. Ann Neurol 44 (1998) 313-316